This research was funded by grants from the Ministry of Defense and the Foundation JCRT.With 180,000 men diagnosed with prostate cancer every year, is one of the most common cancers in the country. For this reason, was cited as a good marker for health care spending in general, reflects broader trends in the United States. A new study from the Dana-Farber / Brigham and Women Cancer Center shows that the more expensive new treatment options for prostate cancer were adopted rapidly and widely in the 2002 to 2005 without evidence of their cost effectiveness, and can provide explanations for accounts for which health care spending by 17 per cent of the GDP of the nation.
The researchers also report that Medicare spending on the latest treatment options was significantly higher compared to traditional treatments, with the difference between IMRT and 3D-CRT are almost $ 11 000 per patient and the difference between robot-assisted prostatectomy and open radical prostatectomy is $ 293, although the authors suggest that this is an underestimate of the differences in the cost base in the field of surgery, because it does not include the cost of purchase and maintenance of the robot. After extrapolating these data to the total population of the United States, researchers have increased the costs adding up to nearly 350 million in 2005, the latest treatment options compared to traditional therapy, alternative and cheaper for people diagnosed with cancer prostate.
In an era of limited resources, it is important for us as a society to take stock of how we spend our money, said Paul Nguyen, MD, lead author of the study and a radiation oncologist at the / Dana-Farber Cancer Center, Brigham and women. We do not believe that these patterns are unique to prostate cancer, but used as an example and found that the United States, the latest technologies and most expensive were rapidly adopted before we knew if they were worth the extra cost, or, in the case of robotic surgery, which offer advantages over standard treatment.
This research is published online March 14 and will appear in an upcoming print edition of the Journal of Clinical Oncology.
Many people consider them unattractive. ?I had several programs on skin biomechanics and transdermal drug delivery. (.
In both tests, the difference between the treated side and control side were very important, the researchers said
apple live blog ohio primary cell phone jammer sandra fluke g8 summit netanyahu aipac
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.